Related Experiment Video
Updated: Jul 18, 2026
06:28
E-Patient Counseling Trial (E-PACO): Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
Published on: August 1, 2019
Pharmacist-supported medication review training for general practitioners: feasibility and acceptability
Janet Krska1, David Gill, Denise Hansford
1Angus Local Health Care Co-operative (LHCC), NHS Tayside, Arbroath Infirmary, Arbroath, Angus, UK.
Medical Education
|November 23, 2006
Summary
Pharmacist-led training for general practitioners (GPs) on medication review is feasible and well-received. However, time constraints may hinder the integration of medication reviews into routine primary care.
Area of Science:
- Pharmaceutical Practice
- General Practice
- Health Services Research
Background:
- Medication reviews are crucial for optimizing patient outcomes.
- General practitioners (GPs) require effective training to conduct comprehensive medication reviews.
- Practice pharmacists can play a role in delivering this training.
Purpose of the Study:
- To assess the feasibility and acceptability of training general practitioners (GPs) in medication review.
- To evaluate the effectiveness of practice pharmacists in delivering this training.
Main Methods:
- A 1-hour practice-based training session was delivered by pharmacists to GPs.
- Funded locum cover was provided for GPs to conduct patient medication reviews.
- Patient notes were reviewed collaboratively, followed by independent GP reviews.
- Postal questionnaires were used to gather GP feedback on the training.
Main Results:
- 51/74 GPs from 10/17 practices received training.
- Common issues identified included medication discrepancies and ineffective treatments.
- A median of 5 actions per patient were taken, with 2 prescribing changes.
- 80% of patients had at least one prescribing record change.
- Most GPs found medication review important and were satisfied with the training, with increased confidence in 52%.
Conclusions:
- Pharmacist-led training for GPs on medication review is feasible and acceptable.
- Time constraints represent a significant barrier to implementing medication reviews in routine practice.
Related Concept Videos
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
01:15Drug Dosage Regimen: Overview
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
01:26Drug Administration and Therapy Phases: Overview
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
01:19Pharmacovigilance
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
01:28Dosage Regimens: Designs and Approaches
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...